Avadel Pharmaceuticals PLC
$ 21.64
0.00%
12 Feb - close price
- Market Cap 2,123,998,000 USD
- Current Price $ 21.64
- High / Low $ 21.64 / 21.64
- Stock P/E N/A
- Book Value 1.01
- EPS N/A
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE N/A %
- 52 Week High 23.57
- 52 Week Low 6.38
About
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Analyst Target Price
$20.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-07 | 2025-05-06 | 2025-03-03 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-09 | 2023-05-04 | 2023-03-29 |
| Reported EPS | 0.0002 | 0.1 | -0.05 | -0.05 | -0.0273 | -0.14 | -0.3 | -0.29 | -0.41 | -0.83 | -0.48 | -0.46 |
| Estimated EPS | 0.07 | 0.03 | -0.07 | -0.02 | -0.05 | -0.16 | -0.21 | -0.26 | -0.37 | -0.38 | -0.38 | -0.27 |
| Surprise | -0.0698 | 0.07 | 0.02 | -0.03 | 0.0227 | 0.02 | -0.09 | -0.03 | -0.04 | -0.45 | -0.1 | -0.19 |
| Surprise Percentage | -99.7143% | 233.3333% | 28.5714% | -150% | 45.4% | 12.5% | -42.8571% | -11.5385% | -10.8108% | -118.4211% | -26.3158% | -70.3704% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0941 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVDL
2026-02-16 12:57:48
Alkermes plc has completed its $2.3 billion acquisition of Avadel Pharmaceuticals plc, adding the FDA-approved narcolepsy drug LUMRYZ to its commercial portfolio. This strategic move aims to accelerate Alkermes' entry into the sleep medicine market, strengthen its pipeline, and enhance commercial capabilities, with the deal expected to be accretive by 2026. The acquisition was financed through a combination of cash and new debt, and Alkermes plans to provide updated financial expectations for the combined entity in February 2026.
2026-02-12 23:57:07
Alkermes has completed its acquisition of Avadel Pharmaceuticals, integrating the FDA-approved narcolepsy treatment LUMRYZ into its commercial portfolio and strengthening its presence in the sleep medicine market. This deal, finalized on February 12, 2026, is expected to be accretive in 2026 and includes the pipeline candidate valiloxybate, enhancing Alkermes' capabilities in treating central disorders of hypersomnolence. Alkermes financed the acquisition with cash and term loans, planning to rapidly pay down debt using business cash flows.
2026-02-12 13:27:59
Alkermes PLC has finalized its acquisition of Avadel Pharmaceuticals plc, a strategic move aimed at rapidly entering the sleep medication market. This acquisition is expected to bolster Alkermes' presence in the specialty pharmaceutical sector and leverage Avadel's expertise in sleep disorder treatments for future growth.
2026-02-12 11:27:59
RFG Advisory LLC has acquired a new position in Avadel Pharmaceuticals PLC (NASDAQ: AVDL), purchasing 73,944 shares valued at approximately $1.13 million. This comes as institutional investors and hedge funds significantly increase their stakes, with total institutional ownership reaching 69.19%. Despite this institutional accumulation, analyst sentiment has cooled, leading to multiple downgrades and a consensus "Hold" rating with a $20.00 price target, while the stock currently trades around $21.64.
2026-02-12 07:28:14
Avadel Pharmaceuticals Plc (NASDAQ: AVDL) is currently exhibiting a neutral near and mid-term outlook with a long-term positive bias, according to AI analysis. The analysis identifies a mid-channel oscillation pattern and presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. Key findings include a 29.7:1 risk-reward short setup targeting a 9.2% downside, with specific entry, target, and stop-loss levels provided.
2026-02-10 21:27:33
The Irish High Court has sanctioned the scheme of arrangement for Alkermes to acquire all ordinary shares of Avadel Pharmaceuticals without modification. The scheme is expected to take effect on February 12, 2026, with February 11, 2026, being the last day for Avadel shares to trade on Nasdaq, followed by a trading halt at 8:00 p.m. U.S. Eastern Time. The completion of the transaction still depends on the delivery of the Court Order to the Registrar of Companies.
